Free tool
FAERS Monitor: Auvelity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215430 or its brand name (Auvelity, Bupropion Hydrochloride, Dextromethorphan Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
3,564
Serious
841
24% of reports
Hospitalization
199
Death reported
36
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness328
- feeling abnormal286
- drug ineffective230
- anxiety228
- inappropriate schedule of product administration185
- nausea179
- fatigue177
- depression175
- off label use175
- headache155
- therapy interrupted154
- tremor130
- suicidal ideation128
- somnolence116
- insomnia113
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 17 |
| 2023 | 687 |
| 2024 | 944 |
| 2025 | 1,091 |
| 2026 | 820 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 154 | 12.7 | 10.9 | 1,657 |
| suicidal ideationSignal | 128 | 8.3 | 7.0 | 812 |
| feeling abnormalSignal | 286 | 7.1 | 6.3 | 1,494 |
| inappropriate schedule of product administrationSignal | 185 | 6.1 | 5.3 | 783 |
| anxietySignal | 228 | 4.7 | 4.2 | 676 |
| tremorSignal | 130 | 4.6 | 3.9 | 368 |
| depressionSignal | 175 | 4.5 | 3.9 | 485 |
| dizzinessSignal | 328 | 3.9 | 3.5 | 716 |
| somnolenceSignal | 116 | 3.4 | 2.8 | 196 |
| insomniaSignal | 113 | 2.5 | 2.1 | 102 |
| headache | 155 | 1.5 | 1.3 | 23 |
| fatigue | 177 | 1.3 | 1.2 | 16 |
| nausea | 179 | 1.3 | 1.2 | 15 |
| off label use | 175 | 1.2 | 1.0 | 5 |
| drug ineffective | 230 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.